hookipa biotech ag logo

Hookipa Biotech AG

We are a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology Hookipa Biotech is a clinical stage company developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms.

The company is founded by Nobel Prize Winner Prof. Dr. Rolf Zinkernagels laboratory and is focused on the development of its lead candidate HB101, a vaccine for immunization against cytomegalovirus (CMV).

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.hookipapharma.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Helmut-Qualtinger-Gasse 21030
Vienna
Austria
Email
Contact Number
+43 1 890 63 60

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/hookipa-biotech-ag” connections=”true” suffix=””]

Hookipa owns two key technologies – Vaxwaveë is replication-defective viral vector platform based on lymphocytic choriomeningitis virus (LCMV) and ability to stimulate both potent B-cell and CD8+ T-cell immune responses. Unlike other vectors, Vaxwaveë vaccines can be administered repeatedly to boost the immune system.
Hookipas TheraTë platform is based on an attenuated replicating virus capable of eliciting the most potent T cell responses, thus turning _cold tumors hotÓ. In preclinical studies, TheraTë has proven to be safe in animals as well as capable of eliciting uniquely potent antigen-specific CD8+ cytotoxic T cell responses and strong tumor control in mice.

In Dec 2017, Hookipa raised $60 Mn in Series C funding round. Key investors includes HBM Partners, Hillhouse Capital, Sirona Capital, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures, BioMedPartner and Gilead. In earlier rounds it raised ‹ 27 Mn in equity finance.